Pre-clinical evaluation of a replication-competent recombinant adenovirus serotype 4 vaccine expressing influenza H5 hemagglutinin

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Alexander, Jeff ^a   Ward, Simone ^a   Mendy, Jason ^a   Manayani, Darly J ^a   Farness, Peggy ^a   Avanzini, Jenny B ^a   Guenther, Ben ^a   Garduno, Fermin ^a   Jow, Lily ^a   Snarsky, Victoria ^a   Ishioka, Glenn ^a   Dong, Xin ^a   Vang, Lo ^a   Newman, Mark J ^a   Mayall, Tim ^a  

^a PaxVax Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; AVIAN INFLUENZA H5N1 HEMAGGLUTININ; AVIAN INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT ADENOVIRUS SEROTYPE 4 AVIAN INFLUENZA H5N1 HEMAGGLUTININ VACCINE; UNCLASSIFIED DRUG; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG PURIFICATION; DRUG SAFETY; DRUG SYNTHESIS; EMBRYO; FLOW CYTOMETRY; GENE DELETION; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; INFLUENZA A (H5N1); INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS ATTENUATION; VIRUS RECOMBINATION; VIRUS REPLICATION; WESTERN BLOTTING; WILD TYPE; ADENOVIRUS; AMINO ACID SEQUENCE; ANIMAL; CELL LINE; CHEMISTRY; CLASSIFICATION; GENE VECTOR; GENETIC REASSORTMENT; GENETIC RECOMBINATION; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNIZATION; IMMUNOLOGY; LUNG; MOLECULAR GENETICS; ORTHOMYXOVIRUS INFECTION; PATHOLOGY; PHYSIOLOGY; SEROTYPING; SPECIES DIFFERENCE; SURVIVAL; VIROLOGY; VIRUS LOAD;

ADENOVIRIDAE; AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CELL LINE; GENETIC VECTORS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; REASSORTANT VIRUSES; RECOMBINATION, GENETIC; SEROTYPING; SPECIES SPECIFICITY; SURVIVAL ANALYSIS; VIRAL LOAD; VIRUS REPLICATION;

EID: 84857177060     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031177     Document Type: Article

References (60)

1. Alexander DJ, (2007) An overview of the epidemiology of avian influenza. Vaccine 25: 5637-5644.
2. Belser JA, Blixt O, Chen LM, Pappas C, Maines TR, et al. (2008) Contemporary North American influenza H7 viruses possess human receptor specificity: Implications for virus transmissibility. Proc Natl Acad Sci U S A 105: 7558-7563.
3. Butt KM, Smith GJ, Chen H, Zhang LJ, Leung YH, et al. (2005) Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 43: 5760-5767.
4. Webster RG, Peiris M, Chen H, Guan Y, (2006) H5N1 outbreaks and enzootic influenza. Emerg Infect Dis 12: 3-8.
5. Neumann G, Chen H, Gao GF, Shu Y, Kawaoka Y, (2010) H5N1 influenza viruses: outbreaks and biological properties. Cell Res 20: 51-61.
6. Aaman M, Ashraf S, Dreyer NA, Toovey S, (2011) Human infection with avian influenza virus, Pakistan, 2007. Emerg Infect Dis 17: 1056-1059.
7. Wood JM, Robertson JS, (2004) From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat Rev Microbiol 2: 842-847.
8. Gaydos CA, Gaydos JC, (1995) Adenovirus vaccines in the U.S. military. Mil Med 160: 300-304.
9. Gurwith MJ, Horwith GS, Impellizzeri CA, Davis AR, Lubeck MD, et al. (1989) Current use and future directions of adenovirus vaccine. Semin Respir Infect 4: 299-303.
10. Kajon AE, Moseley JM, Metzgar D, Huong HS, Wadleigh A, et al. (2007) Molecular epidemiology of adenovirus type 4 infections in US military recruits in the postvaccination era (1997-2003). J Infect Dis 196: 67-75.
11. Alcock R, Cottingham MG, Rollier CS, Furze J, De Costa SD, et al. (2010) Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Science translational medicine 2: 19ra12.
12. Appaiahgari MB, Saini M, Rauthan M, Jyoti, Vrati S, (2006) Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 8: 92-104.
13. Arevalo MT, Xu Q, Paton JC, Hollingshead SK, Pichichero ME, et al. (2009) Mucosal vaccination with a multicomponent adenovirus-vectored vaccine protects against Streptococcus pneumoniae infection in the lung. FEMS Immunol Med Microbiol 55: 346-351.
14. Barouch DH, Nabel GJ, (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16: 149-156.
15. Chengalvala MV, Bhat BM, Bhat R, Lubeck MD, Mizutani S, et al. (1994) Immunogenicity of high expression adenovirus-hepatitis B virus recombinant vaccines in dogs. J Gen Virol 75 (Pt 1): 125-131.
16. Khanam S, Pilankatta R, Khanna N, Swaminathan S, (2009) An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27: 6011-6021.
17. Knowles MK, Nadin-Davis SA, Sheen M, Rosatte R, Mueller R, et al. (2009) Safety studies on an adenovirus recombinant vaccine for rabies (AdRG1.3-ONRAB) in target and non-target species. Vaccine 27: 6619-6626.
18. Lubeck MD, Davis AR, Chengalvala M, Natuk RJ, Morin JE, et al. (1989) Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 86: 6763-6767.
19. Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, et al. (2009) Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine. PLoS One 4: e5308.
20. Tacket CO, Losonsky G, Lubeck MD, Davis AR, Mizutani S, et al. (1992) Initial safety and immunogenicity studies of an oral recombinant adenohepatitis B vaccine. Vaccine 10: 673-676.
21. Wang J, Thorson L, Stokes RW, Santosuosso M, Huygen K, et al. (2004) Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis. J Immunol 173: 6357-6365.
22. Limbach KJ, Richie TL, (2009) Viral vectors in malaria vaccine development. Parasite Immunol 31: 501-519.
23. Cerullo V, Seiler MP, Mane V, Brunetti-Pierri N, Clarke C, et al. (2007) Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther 15: 378-385.
24. Hartman ZC, Black EP, Amalfitano A, (2007) Adenoviral infection induces a multi-faceted innate cellular immune response that is mediated by the toll-like receptor pathway in A549 cells. Virology 358: 357-372.
25. Huang X, Yang Y, (2009) Innate immune recognition of viruses and viral vectors. Hum Gene Ther 20: 293-301.
26. Lore K, Adams WC, Havenga MJ, Precopio ML, Holterman L, et al. (2007) Myeloid and plasmacytoid dendritic cells are susceptible to recombinant adenovirus vectors and stimulate polyfunctional memory T cell responses. J Immunol 179: 1721-1729.
27. Muruve DA, Barnes MJ, Stillman IE, Libermann TA, (1999) Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 10: 965-976.
28. Zhu J, Huang X, Yang Y, (2007) Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and-independent pathways. J Virol 81: 3170-3180.
29. Gao W, Soloff AC, Lu X, Montecalvo A, Nguyen DC, et al. (2006) Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 80: 1959-1964.
30. Hoelscher MA, Garg S, Bangari DS, Belser JA, Lu X, et al. (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367: 475-481.
31. Hoelscher MA, Singh N, Garg S, Jayashankar L, Veguilla V, et al. (2008) A broadly protective vaccine against globally dispersed clade 1 and clade 2 H5N1 influenza viruses. J Infect Dis 197: 1185-1188.
32. Holman DH, Wang D, Raja NU, Luo M, Moore KM, et al. (2008) Multi-antigen vaccines based on complex adenovirus vectors induce protective immune responses against H5N1 avian influenza viruses. Vaccine 26: 2627-2639.
33. Park KS, Lee J, Ahn SS, Byun YH, Seong BL, et al. (2009) Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 395: 182-189.
34. Steitz J, Barlow PG, Hossain J, Kim E, Okada K, et al. (2010) A candidate H1N1 pandemic influenza vaccine elicits protective immunity in mice. PLoS One 5: e10492.
35. Soboleski MR, Gabbard JD, Price GE, Misplon JA, Lo C-Y, et al. (2011) Cold-adapted influenza and recombinant adenovirus vaccines induce cross-protective immunity against pH1N1 challenge in mice. PLoS One 6: e21937.
36. Rollier CS, Reyes-Sandoval A, Cottingham MG, Ewer K, Hill AV, (2011) Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 23: 377-382.
37. Robert-Guroff M, (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18: 546-556.
38. Cox RJ, Brokstad KA, Ogra P, (2004) Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 59: 1-15.
39. Fulginiti VA, Eller JJ, Downie AW, Kempe CH, (1967) Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202: 1075-1080.
40. Johnson PR Jr, Feldman S, Thompson JM, Mahoney JD, Wright PF, (1985) Comparison of long-term systemic and secretory antibody responses in children given live, attenuated, or inactivated influenza A vaccine. J Med Virol 17: 325-335.
41. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, et al. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8: 453-465.
42. Vita R, Zarebski L, Greenbaum JA, Emami H, Hoof I, et al. (2010) The immune epitope database 2.0. Nucleic Acids Res 38: D854-862.
43. Dubey S, Clair J, Fu TM, Guan L, Long R, et al. (2007) Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 45: 20-27.
44. Reed Lj, Muench H, (1938) A simple method of estimating fifty percent endpoints. The Am J Hyg 27: 493-497.
45. Hsu KH, Lubeck MD, Bhat BM, Bhat RA, Kostek B, et al. (1994) Efficacy of adenovirus-vectored respiratory syncytial virus vaccines in a new ferret model. Vaccine 12: 607-612.
46. Kaneko H, Mori S, Suzuki O, Iida T, Shigeta S, et al. (2004) The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antiviral Res 61: 63-66.
47. Pedreira FA, Tauraso NM, Palmer AE, Shelokov A, Kirschstein RL, (1968) Attempts to infect rhesus monkeys with human type 4 adenovirus. Proc Soc Exp Biol Med 129: 472-477.
48. Roelvink PW, Lizonova A, Lee JG, Li Y, Bergelson JM, et al. (1998) The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F. J Virol 72: 7909-7915.
49. Belyakov IM, Moss B, Strober W, Berzofsky JA, (1999) Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci U S A 96: 4512-4517.
50. Couch RB, Chanock RM, Cate TR, Lang DJ, Knight V, et al. (1963) Immunization with Types 4 and 7 Adenovirus by Selective Infection of the Intestinal Tract. Am Rev Respir Dis 88: SUPPL 394-403.
51. Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, et al. (2008) Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice. PLoS One 3: e3548.
52. Gabitzsch ES, Xu Y, Yoshida LH, Balint J, Amalfitano A, et al. (2009) Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 27: 6394-6398.
53. Lyons A, (2008) A double-blind, placebo-controlled study of the safety and immunogenicity of live, oral type 4 and type 7 adenovirus vaccines in adults. Vaccine 26: 2890-2898.
54. Santosuosso M, Zhang X, McCormick S, Wang J, Hitt M, et al. (2005) Mechanisms of mucosal and parenteral tuberculosis vaccinations: adenoviral-based mucosal immunization preferentially elicits sustained accumulation of immune protective CD4 and CD8 T cells within the airway lumen. J Immunol 174: 7986-7994.
55. Thacker EE, Timares L, Matthews QL, (2009) Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines 8: 761-777.
56. Top FH Jr, Grossman RA, Bartelloni PJ, Segal HE, Dudding BA, et al. (1971) Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis 124: 148-154.
57. Tucker SN, Tingley DW, Scallan CD, (2008) Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev Vaccines 7: 25-31.
58. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, et al. (2003) Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77: 10780-10789.
59. Ludwig SL, Brundage JF, Kelley PW, Nang R, Towle C, et al. (1998) Prevalence of antibodies to adenovirus serotypes 4 and 7 among unimmunized US Army trainees: results of a retrospective nationwide seroprevalence survey. J Infect Dis 178: 1776-1778.
60. Narang A, Bose A, Pandit AN, Dutta P, Kang G, et al. (2009) Immunogenicity, reactogenicity and safety of human rotavirus vaccine (RIX4414) in Indian infants. Hum Vaccin 5: 414-419.